☰

Matthew J. Frank, Ph.D. - Publications

Affiliations: 
2009 University of California, Los Angeles, Los Angeles, CA 
Tree Info Similar researchers PubMed Report error

39 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Shree T, Haebe SE, Czerwinski DK, Eckhert E, Day G, Sathe A, Grimes SM, Frank MJ, Maeda L, Alizadeh AA, Advani RH, Hoppe RT, Long SR, Martin BA, Ozawa MG, et al. A clinical trial of therapeutic vaccination in lymphoma with serial tumor sampling and single cell analysis. Blood Advances. PMID 37939259 DOI: 10.1182/bloodadvances.2023011589  0.344
2023 Younes S, Zhao S, Bharadwaj S, Mosquera AP, Libert D, Johnsrud A, Majzner RG, Miklos DB, Frank MJ, Natkunam Y. Detection of Aberrant CD58 Expression in a Wide Spectrum of Lymphoma Subtypes: Implications for Treatment Resistance. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 100256. PMID 37391168 DOI: 10.1016/j.modpat.2023.100256  0.336
2023 Nie EH, Ahmadian SS, Bharadwaj SN, Acosta-Alvarez L, Threlkeld ZD, Frank MJ, Miklos DB, Monje M, Scott BJ, Vogel H. Multifocal demyelinating leukoencephalopathy and oligodendroglial lineage cell loss with immune effector cell-associated neurotoxicity syndrome (ICANS) following CD19 CAR T-cell therapy for mantle cell lymphoma. Journal of Neuropathology and Experimental Neurology. PMID 36592076 DOI: 10.1093/jnen/nlac121  0.361
2022 Sworder BJ, Kurtz DM, Alig SK, Frank MJ, Shukla N, Garofalo A, Macaulay CWM, Shahrokh Esfahani M, Olsen MN, Hamilton J, Hosoya H, Hamilton M, Spiegel JY, Baird JH, Sugio T, et al. Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas. Cancer Cell. PMID 36584673 DOI: 10.1016/j.ccell.2022.12.005  0.439
2022 Good Z, Spiegel JY, Sahaf B, Malipatlolla MB, Ehlinger ZJ, Kurra S, Desai MH, Reynolds WD, Wong Lin A, Vandris P, Wu F, Prabhu S, Hamilton MP, Tamaresis JS, Hanson PJ, ... ... Frank MJ, et al. Post-infusion CAR T cells identify patients resistant to CD19-CAR therapy. Nature Medicine. PMID 36097223 DOI: 10.1038/s41591-022-01960-7  0.366
2022 Vu K, Frank MJ. CAR T-cell therapy for mantle cell lymphoma with central nervous system relapse. Blood Advances. PMID 35895518 DOI: 10.1182/bloodadvances.2022008031  0.348
2022 Esfahani MS, Hamilton EG, Mehrmohamadi M, Nabet BY, Alig SK, King DA, Steen CB, Macaulay CW, Schultz A, Nesselbush MC, Soo J, Schroers-Martin JG, Chen B, Binkley MS, Stehr H, ... ... Frank MJ, et al. Inferring gene expression from cell-free DNA fragmentation profiles. Nature Biotechnology. PMID 35361996 DOI: 10.1038/s41587-022-01222-4  0.348
2021 Mooney KL, Czerwinski DK, Shree T, Frank MJ, Haebe S, Martin BA, Testa S, Levy R, Long SR. Serial FNA allows direct sampling of malignant and infiltrating immune cells in patients with B-cell lymphoma receiving immunotherapy. Cancer Cytopathology. PMID 34780125 DOI: 10.1002/cncy.22531  0.376
2021 Frank MJ, Hossain NM, Bukhari A, Dean E, Spiegel JY, Claire GK, Kirsch I, Jacob AP, Mullins CD, Lee LW, Kong KA, Craig J, Mackall CL, Rapoport AP, Jain MD, et al. Monitoring of Circulating Tumor DNA Improves Early Relapse Detection After Axicabtagene Ciloleucel Infusion in Large B-Cell Lymphoma: Results of a Prospective Multi-Institutional Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2100377. PMID 34133196 DOI: 10.1200/JCO.21.00377  0.415
2021 Baird JH, Epstein DJ, Tamaresis JS, Ehlinger Z, Spiegel JY, Craig J, Claire GK, Frank MJ, Muffly L, Shiraz P, Meyer E, Arai S, Brown JW, Johnston L, Lowsky R, et al. Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma. Blood Advances. 5: 143-155. PMID 33570626 DOI: 10.1182/bloodadvances.2020002732  0.378
2020 Baird JH, Frank MJ, Craig J, Patel S, Spiegel JY, Sahaf B, Oak JS, Younes S, Ozawa M, Yang E, Natkunam Y, Tamaresis JS, Ehlinger Z, Reynolds WD, Arai S, et al. CD22-Directed CAR T-Cell Therapy Induces Complete Remissions in CD19-Directed CAR-Refractory Large B-Cell Lymphoma. Blood. PMID 33512414 DOI: 10.1182/blood.2020009432  0.397
2020 Lemieux C, Johnston LJ, Lowsky R, Muffly LS, Craig JK, Shiraz P, Rezvani A, Frank MJ, Weng WK, Meyer E, Shizuru J, Arai S, Negrin R, Miklos DB, Sidana S. Outcomes with Autologous or Allogeneic Stem Cell Transplantation in Patients with Plasma Cell Leukemia in the Era of Novel Agents. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 32961371 DOI: 10.1016/J.Bbmt.2020.08.035  0.335
2020 Frank MJ, Khodadoust MS, Czerwinski DK, Haabeth OAW, Chu MP, Miklos DB, Advani RH, Alizadeh AA, Gupta NK, Maeda LS, Reddy SA, Laport GG, Meyer EH, Negrin RS, Rezvani AR, et al. Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial. The Journal of Experimental Medicine. 217. PMID 32558897 DOI: 10.1084/Jem.20191712  0.425
2020 Frank MJ, Olsson N, Huang A, Tang SW, Negrin RS, Elias JE, Meyer EH. A novel antibody-cell conjugation method to enhance and characterize cytokine-induced killer cells. Cytotherapy. 22: 135-143. PMID 32171435 DOI: 10.1016/J.Jcyt.2020.01.003  0.425
2019 Frank MJ, Hossain NM, Bukhari AA, Dean E, Spiegel JY, Claire GK, Kirsch I, Jacob A, Mullins CD, Lee LW, Kong KA, Craig JK, Mackall C, Rapoport A, Dahiya S, et al. Monitoring ctDNA in r/r DLBCL patients following the CAR T-cell therapy axicabtagene ciloleucel: Day 28 landmark analysis. Journal of Clinical Oncology. 37: 7552-7552. DOI: 10.1200/Jco.2019.37.15_Suppl.7552  0.374
2019 Frank MJ, Hossain N, Bukhari A, Dean E, Spiegel JY, Claire GK, Kirsch IM, Jacob AP, Mullins CD, Lee LW, Kong KA, Craig J, Mackall CL, Rapoport AP, Dahiya S, et al. Detectable Circulating Tumor DNA 28 Days after the CD19 CAR T-Cell Therapy, Axicabtagene Ciloleucel, Is Associated with Poor Outcomes in Patients with Diffuse Large B-Cell Lymphoma Blood. 134: 884-884. DOI: 10.1182/Blood-2019-132057  0.372
2019 Good Z, Spiegel JY, Sahaf B, Malipatlolla MB, Frank MJ, Baird J, Muffly LS, Claire GK, Craig J, Kong KA, Bendall S, Miklos DB, Mackall CL. Identification of Two CAR T-Cell Populations Associated with Complete Response or Progressive Disease in Adult Lymphoma Patients Treated with Axi-Cel Blood. 134: 779-779. DOI: 10.1182/Blood-2019-130815  0.416
2019 Shree T, Khodadoust MS, Czerwinski DK, Frank MJ, Hong WX, Greenstein R, Long SR, Martin B, Levy R. A Phase I/II Trial of Intratumoral CpG, Local Low-Dose Radiation, and Oral Ibrutinib in Patients with Low-Grade B-Cell Lymphoma Blood. 134: 2825-2825. DOI: 10.1182/Blood-2019-129661  0.46
2019 Schultz LM, Muffly LS, Spiegel JY, Ramakrishna S, Hossain N, Baggott C, Sahaf B, Patel S, Craig J, Yoon J, Kadapakkam M, Majzner RG, Frank MJ, Erickson C, Marcy AC, et al. Phase I Trial Using CD19/CD22 Bispecific CAR T Cells in Pediatric and Adult Acute Lymphoblastic Leukemia (ALL) Blood. 134: 744-744. DOI: 10.1182/Blood-2019-129411  0.405
2019 Sworder B, Kurtz DM, Macaulay C, Frank MJ, Alig S, Garofalo A, Sahaf B, Esfahani MS, Spiegel JY, Oak J, Beygi S, Jin MC, Chabon JJ, Khodadoust MS, Majzner RG, et al. Circulating DNA for Molecular Response Prediction, Characterization of Resistance Mechanisms and Quantification of CAR T-Cells during Axicabtagene Ciloleucel Therapy Blood. 134: 550-550. DOI: 10.1182/Blood-2019-129015  0.435
2019 Shree T, Khodadoust MS, Czerwinski D, Frank MJ, Hong WX, Greenstein R, Guo S, Long S, Martin BA, Levy R. Abstract CT133: Interim results of a Phase I/II trial of intratumoral CpG, local low-dose radiation, and oral ibrutinib in patients with low-grade B-cell lymphoma Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-Ct133  0.482
2019 Shree T, Khodadoust M, Czerwinski D, Frank M, Hong W, Greenstein R, Long S, Martin B, Levy R. A PHASE I/II TRIAL OF IBRUTINIB, INTRATUMORAL CPG AND LOCAL RADIATION IN PATIENTS WITH LOW-GRADE B-CELL LYMPHOMA: INTERIM CLINICAL AND CORRELATIVE RESULTS Hematological Oncology. 37: 122-123. DOI: 10.1002/Hon.82_2629  0.413
2018 Frank MJ, Reagan PM, Bartlett NL, Gordon LI, Friedberg JW, Czerwinski DK, Long SR, Hoppe RT, Janssen RS, Candia AF, Coffman RL, Levy R. In Situ Vaccination with a TLR 9 Agonist and Local Low Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma. Cancer Discovery. PMID 30154192 DOI: 10.1158/2159-8290.Cd-18-0743  0.39
2018 Czerwinski DK, Frank MJ, Shree T, Khodadoust MS, Long SR, Levy R. Intratumoral Injection of CpG-ODN Plus Systemic Ibrutinib Induces an Anti-Tumor Immune Response Affecting T Cell Subsets in the Microenvironment of Both Injected and Non-Injected Tumor Sites in Patients with Low-Grade Lymphoma Blood. 132: 1612-1612. DOI: 10.1182/Blood-2018-99-119931  0.477
2018 Spiegel JY, Sahaf B, Hossain N, Frank MJ, Claire G, Abramian M, Latchford T, Villa B, Cancilla J, Oak J, Natkunam Y, Long SR, Arai S, Johnston LJ, Lowsky R, et al. Elevated Axicabtagene Ciloleucel (CAR-19) Expansion By Immunophenotyping Is Associated with Toxicity in Diffuse Large B-Cell Lymphoma Blood. 132: 576-576. DOI: 10.1182/Blood-2018-99-113261  0.408
2018 Hossain N, Sahaf B, Abramian M, Spiegel JY, Kong K, Kim S, Mavroukakis S, Oak J, Natkunam Y, Meyer EH, Frank MJ, Feldman SA, Long SR, Qin H, Fry TJ, et al. Phase I Experience with a Bi-Specific CAR Targeting CD19 and CD22 in Adults with B-Cell Malignancies Blood. 132: 490-490. DOI: 10.1182/Blood-2018-99-110142  0.42
2017 Frank MJ, Huang A, Tang S, Negrin RS, Hsiao S, Meyer EH. A Novel Antibody-Cell Conjugation Method to Enhance Cellular Therapies for the Treatment of Hematological Malignancies Blood. 130: 1532-1532. DOI: 10.1182/Blood.V130.Suppl_1.1532.1532  0.492
2017 Frank M, Khodadoust M, Chu M, Kohrt H, Advani R, Alizadeh A, Reddy S, Maeda L, Gupta N, Laport G, Meyer E, Miklos D, Negrin R, Rezvani A, Weng W, et al. PHASE I/II CLINICAL TRIAL OF AN ACTIVATED WHOLE TUMOR CELL VACCINE FOLLOWED BY TRANSFER OF IMMUNE T CELLS IN PATIENTS WITH MANTLE CELL LYMPHOMA Hematological Oncology. 35: 207-208. DOI: 10.1002/Hon.2438_72  0.426
2016 Levy R, Reagan PM, Friedberg JW, Bartlett NL, Gordon LI, Leung A, Peterkin J, Xing B, Coffman R, Janssen R, Candia A, Khodadoust M, Frank MJ, Long SR, Czerwinski DK, et al. SD-101, a Novel Class C CpG-Oligodeoxynucleotide (ODN) Toll-like Receptor 9 (TLR9) Agonist, Given with Low Dose Radiation for Untreated Low Grade B-Cell Lymphoma: Interim Results of a Phase 1/2 Trial Blood. 128: 2974-2974. DOI: 10.1182/Blood.V128.22.2974.2974  0.385
2016 Czerwinski DK, Long SR, Khodadoust M, Frank MJ, Kardosh A, Okada A, Robinson S, Levy R. Examining the Heterogeneity of Follicular Lymphoma By Multi-Parameter Flow Cyotmetry in Previously Untreated Patients Blood. 128: 2947-2947. DOI: 10.1182/Blood.V128.22.2947.2947  0.547
2016 Levy R, Bartlett N, Friedberg J, Reagan P, Gordon L, Bergman C, Coffman R, Janssen R, Candia A, Khodadoust M, Frank M, Long S, Czerwinski D, Chu M, Kohrt H. Abstract CT047: SD-101, a novel intratumoral class C CpG-ODN, given with low-dose radiation in patients with untreated low-grade B-cell lymphoma: interim results of a phase I trial Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Ct047  0.405
2015 Czerwinski DK, Long SR, Khodadoust M, Frank MJ, Chu MP, Okada A, McDonald KA, Kohrt HE, Bartlett NL, Reagan PM, Friedberg JW, Gordon LI, Coffman R, Janssen R, Levy R. Regulatory T Cells Are Depleted in Low-Grade Lymphoma By the Combination of Local Low-Dose Radiation Followed By Intratumoral CpG-ODN Blood. 126: 1539-1539. DOI: 10.1182/Blood.V126.23.1539.1539  0.493
2015 Chu MP, Brody J, Kohrt HE, Frank MJ, Khodadoust M, Reddy S, Advani RH, Gupta NK, Laport G, Maeda LS, Meyer E, Miklos DB, Negrin R, Rezvani AR, Weng W, et al. Phase I/II Clinical Trial of CpG-Activated Whole Cell Vaccine in Mantle Cell Lymphoma (MCL): Results in Safety and Efficacy from Planned Interim Analysis Blood. 126: 1536-1536. DOI: 10.1182/Blood.V126.23.1536.1536  0.441
2011 Aaltonen T, Álvarez González B, Amerio S, Amidei D, Anastassov A, Annovi A, Antos J, Apollinari G, Appel JA, Apresyan A, Arisawa T, Artikov A, Asaadi J, Ashmanskas W, Auerbach B, ... Frank MJ, et al. Search for B(s)(0) → μ+ μ- and B(0) → μ+ μ- decays with CDF II. Physical Review Letters. 107: 191801. PMID 22181596 DOI: 10.1103/Physrevlett.107.191801  0.319
2009 Balatoni CE, Dawson DW, Suh J, Sherman MH, Sanders G, Hong JS, Frank MJ, Malone CS, Said JW, Teitell MA. Epigenetic silencing of Stk39 in B-cell lymphoma inhibits apoptosis from genotoxic stress. The American Journal of Pathology. 175: 1653-61. PMID 19717643 DOI: 10.2353/Ajpath.2009.090091  0.619
2009 Frank MJ, Dawson DW, Bensinger SJ, Hong JS, Knosp WM, Xu L, Balatoni CE, Allen EL, Shen RR, Bar-Sagi D, Martin GR, Teitell MA. Expression of sprouty2 inhibits B-cell proliferation and is epigenetically silenced in mouse and human B-cell lymphomas. Blood. 113: 2478-87. PMID 19147787 DOI: 10.1182/Blood-2008-05-156943  0.62
2008 Reed J, Frank M, Troke JJ, Schmit J, Han S, Teitell MA, Gimzewski JK. High throughput cell nanomechanics with mechanical imaging interferometry. Nanotechnology. 19: 235101. PMID 20737027 DOI: 10.1088/0957-4484/19/23/235101  0.536
2008 Reed J, Frank M, Troke JJ, Schmit J, Han S, Teitell MA, Gimzewski JK. Imaging interferometry for investigation of mechanics of multiple cells in a large field of view Optics Infobase Conference Papers.  0.515
2007 Fagone P, Sriburi R, Ward-Chapman C, Frank M, Wang J, Gunter C, Brewer JW, Jackowski S. Phospholipid biosynthesis program underlying membrane expansion during B-lymphocyte differentiation. The Journal of Biological Chemistry. 282: 7591-605. PMID 17213195 DOI: 10.1074/Jbc.M608175200  0.322
Show low-probability matches.